Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04149132
Other study ID # PROUD-1
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 30, 2019
Est. completion date June 30, 2020

Study information

Verified date July 2020
Source Hellenic Institute for the Study of Sepsis
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Early management of sepsis is associated with better outcome. However, this requires early recognition of the sepsis host. One recently developed customized pulse photoplethysmography (PPG) device manages to measure nitric oxide (NO) that is released from vascular endothelium and seems promising for earlier sepsis diagnosis than conventional approaches. Aim of the project To evaluate the diagnostic performance of the PPG device for the early diagnosis of sepsis is to evaluate the diagnostic performance of the PPG device for the early diagnosis of sepsis


Description:

Sepsis is a life-threatening syndrome and the most common cause of death nowadays. This syndrome develops as a result of the dysregulated host response to an infectious insult. As such the mainstay of treatment is the early administration of antimicrobials leading to early eradication of the offending pathogen. However, in this statement the key-feature is the definition of what "early" means. Using the retrospective analysis of data associating final outcome from septic shock with the delay in start of antimicrobials from the start of vasopressors in 2713 patients with septic shock, it was found that 79.1% of patients in which this delay was less than one hour survived. Every further hour of delay in start of antibiotics led to 7.6% increase of the risk for unfavorable outcome. These findings were later confirmed from two other analyses. These findings generate two thoughts: a) the above results are based on early recognition of hospital-acquired sepsis that was achievable only because these studies were done in an Intensive Care Unit (ICU) environment in patients under close monitoring. However, early sepsis recognition for a newly admitted patient remains an unmet need; b) all the above results are coming from patients with septic shock where diagnosis had already been established since patients were already on vasopressors.

It is reasonable to hypothesize that if sepsis had been recognized even earlier final outcome would have been even better. Sanmina have developed a non-invasive technique for the measurement of endothelial released nitric oxide (NO) through customized pulse photoplethysmography (PPG). Since NO is released by the vascular endothelium early in the pathogenesis of sepsis it is reasonable to hypothesize that PPG is a technique that can early inform on the risk for a patient with suspicion of an infection to develop sepsis. The time of measurement is less than two minutes. Preliminary data show that the reading of a healthy subject of eight consecutive minutes cannot trace any increase of NO; in sepsis a peak of more than 200 units is shown within the first 40 seconds of measurement.

The development of PPG as a tool for the early diagnosis of sepsis requires a two-stage approach. The first stage is based on the association of PPG readings with the change of the SOFA (sequential organ failure assessment) score and vital signs to define if among patients who eventually develop sepsis, PPG changes will be produced earlier than changes of SOFA scores and of vital signs.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date June 30, 2020
Est. primary completion date May 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age equal to or greater than 18 years

- Both genders

- Written informed consent provided by the patients or by first-degree relatives in case of patients unable to consent.

- Any of two:

Any infection in a patient with total SOFA score equal to 0 or 1 Patient without sepsis prone to the development of sepsis defined as patients with Charlson's Comorbidity Index (CCI) more than 2 irrespective the reason of admission. These patients are considered prone to infection based on previous findings of our group showing that CCI more than 2 is an independent predisposing factor for sepsis

Exclusion Criteria:

- Age below 18 years

- Denial to consent

- Any stage 4 malignancy

- Any do not resuscitate decision

- Active tuberculosis (TB) as defined by the co-administration of drugs for the treatment of TB

- Pregnancy or lactation

Study Design


Related Conditions & MeSH terms


Intervention

Device:
pulse photoplethysmography (PPG)
PPG and systolic blood pressure recording will be performed every two hours for three consecutive days. PPG reading will last two minutes and peaks of NO productions will be captured. Day 1 is considered the day of signing the informed consent followed by the first recording. On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients
Diagnostic Test:
Measurements of nitric oxide (NO) and malondialdehyde (MDA)
On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients. NO will be measured in serum samples by the Griess reaction. MDA that is considered an index of oxidant status will be measured in serum samples by the thiobarbiturate assay and analysis by high-performance liquid chromatography (HPLC)

Locations

Country Name City State
Greece 2nd Department of Critical Care, "Attikon" University Hospital, National and Kapodistrian University of Athens, Medical School Athens
Greece 4th Department of Internal Medicine, "Attikon" University Hospital, National and Kapodistrian University of Athens, Medical School Athens
Greece Department of Clinical Therapeutics, "Alexandra" General Hospital of Athens, National and Kapodistrian University of Athens, Medical School Athens
Greece Intensive Care Unit, "Korgialenio - Benakio" General Hospital of Athens Athens

Sponsors (1)

Lead Sponsor Collaborator
Hellenic Institute for the Study of Sepsis

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity of PPG for the diagnosis of sepsis. Sensitivity of PPG for the diagnosis of sepsis. 72 hours
Secondary Correlation of PPG (absolute number) with qSOFA score (absolute number) Correlation of PPG (absolute number) with qSOFA score (absolute number) 72 hours
Secondary Correlation of PPG (absolute number) with SOFA score (absolute number) Correlation of PPG (absolute number) with SOFA score (absolute number) 72 hours
Secondary Correlation of time (in minutes) of sepsis diagnosis between PPG (absolute number) and SOFA score (absolute number) Correlation of time (in minutes) of sepsis diagnosis between PPG (absolute number) and SOFA score (absolute number) 72 hours
Secondary Correlation of time (in minutes) of sepsis diagnosis between PPG (absolute number) and hypotension (mmHg) Correlation of time (in minutes) of sepsis diagnosis between PPG (absolute number) and hypotension (mmHg) 72 hours
Secondary The specificity, positive predictive value (PPV) and negative predictive value (NPV) of PPG for the diagnosis of sepsis The specificity, positive predictive value (PPV) and negative predictive value (NPV) of PPG for the diagnosis of sepsis 72 hours
Secondary The sensitivity, specificity, PPV and NPV of PPG for the prognosis of 28-day outcome The sensitivity, specificity, PPV and NPV of PPG for the prognosis of 28-day outcome 28 days
Secondary Correlation of PPG (absolute number) with circulating levels of NO (µmol/l) and MDA (µmol/l) The association between PPG and circulating levels of NO and MDA 72 hours
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3